PRECIGEN, INC. Research and Development Asset Acquired Other than Through Business Combination, Written-off
PRECIGEN, INC. (PGEN) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2021-03-01
- PRECIGEN, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- PRECIGEN, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2018-12-31 was $228.03M.
- PRECIGEN, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2017-12-31 was $0.00.
- PRECIGEN, INC. research and development asset acquired other than through business combination, written-off for fiscal 2020 was $0.00.
- PRECIGEN, INC. research and development asset acquired other than through business combination, written-off for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- PRECIGEN, INC. research and development asset acquired other than through business combination, written-off for fiscal 2018 was $236.75M.
- PRECIGEN, INC. research and development asset acquired other than through business combination, written-off for fiscal 2017 was $0.00.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-01 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 10-K · filed 2021-03-01 | |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-12 | ||
| 2018-12-31 | $228.03M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $236.75M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $8.72M 10-Q · filed 2019-11-12 | ||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 10-K · filed 2020-03-02 | |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-08 | ||
| 2016-12-31 | $0.00 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |